

Gustavo Guimares Moreira Balbi

List of Publications by Citations

Source:

<https://exaly.com/author-pdf/7293549/gustavo-guimaraes-moreira-balbi-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18
papers

85
citations

6
h-index

9
g-index

21
ext. papers

142
ext. citations

3.2
avg, IF

2.22
L-index

#	Paper	IF	Citations
18	Neuro-ophthalmologic manifestations in systemic lupus erythematosus. <i>Lupus</i> , 2017 , 26, 522-528	2.6	22
17	The interplay between tuberculosis and systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2018 , 30, 395-402	5.3	18
16	Ocular involvement in patients with spondyloarthritis. <i>Rheumatology</i> , 2017 , 56, 2060-2067	3.9	14
15	Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature. <i>Lupus</i> , 2020 , 29, 1528-1543	2.6	7
14	New and upcoming treatments in antiphospholipid syndrome: A comprehensive review. <i>Pharmacological Research</i> , 2018 , 133, 108-120	10.2	6
13	Use of synthetic and biologic DMARDs during pregnancy. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 27-39	5.1	6
12	Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS). <i>Advances in Rheumatology</i> , 2020 , 60, 29	3	3
11	Rapidly progressive diffuse systemic sclerosis after local vitamins A, D and E complex injections: literature review and report of two cases. <i>Immunologic Research</i> , 2017 , 65, 285-292	4.3	2
10	Non-criteria Antiphospholipid Antibodies: a narrative review. <i>Revista Da Associação Médica Brasileira</i> , 2020 , 66, 1595-1601	1.4	2
9	Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	2
8	Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.. <i>Lupus</i> , 2022 , 9612033221102073	2.6	2
7	Catastrophic antiphospholipid syndrome: A case with unusual findings revealed in autopsy and a brief literature update. <i>European Journal of Rheumatology</i> , 2017 , 4, 281-283	1.7	1
6	Anorectal diseases in patients with Antiphospholipid syndrome: a cross-sectional study. <i>Advances in Rheumatology</i> , 2020 , 60, 51	3	0
5	Avoiding misclassification of thrombotic primary antiphospholipid syndrome as systemic lupus erythematosus (SLE): What are the best-performing SLE classification criteria?. <i>Lupus</i> , 2021 , 30, 1732-1738	2.6	0
4	CoaguChek [®] XS versus standard laboratory prothrombin time for anticoagulant monitoring in patients with antiphospholipid syndrome.. <i>Lupus</i> , 2022 , 9612033221086134	2.6	0
3	Neoplasia associada ao tratamento das doenças reumáticas. <i>Revista Paulista De Reumatologia</i> , 2020 , 13-16	0.1	
2	Distinct features of youth-onset primary antiphospholipid syndrome. <i>Lupus</i> , 2021 , 30, 1888-1895	2.6	

- 1 Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. *Advances in Rheumatology*, **2021**, 61, 64 3